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Dysregulation of splicing and alternative splicing underlies many genetic and acquired diseases.
We present an overview of recent strategies and successes in modulating splicing therapeutically
in clinical and preclinical contexts. Effective approaches include restoring open reading frames,
influencing alternative splicing, and inducing exon inclusion to generate beneficial proteins and re-
move deleterious ones.Introduction
Splicing of pre-mRNAs removes noncoding introns and gener-
ates protein diversity with alternative inclusion or exclusion of
certain protein-coding exons or parts of exons. Mutations
affecting sequences involved in splicing underlie many genetic
diseases, and alternative splicing is often disrupted in acquired
diseases like cancer. We will discuss recently published
advances in therapeutic strategies to treat diseases arising
from splicing defects. More comprehensive discourses on this
topic include Hammond and Wood (2011).
Exon Skipping to Restore the Open Reading Frame
Exon skipping can be achieved with antisense oligonucleotides
(AONs) and is a strategy for treating Duchenne muscular
dystrophy (DMD). Of all approaches to modulate splicing, this
application is the closest to clinical application. DMD is a severe
muscle-wasting disorder caused by mutations in the DMD gene
encoding dystrophin that links the cytoskeleton to the extracel-
lular matrix of muscle fibers. Point mutations and frame-shifting
deletions lead to premature truncation of protein translation and
render the protein nonfunctional. Restoring the reading frame of
DMD transcripts could be beneficial, as the resulting internally
deleted dystrophins are found in the milder Becker muscular
dystrophy. To achieve exon skipping, AONs target specific
exons in the pre-mRNA, hide them from the splicing machinery,
and cause them to be skipped during the splicing process
(Figure 1A).
Following preclinical tests in patient-derived cell and animal
models, this approach is currently in clinical trials for exon 51
skipping, as this would benefit the largest group of patients.
Two AON chemistries have been developed in parallel: 20-O-
methyl phosphorothioate AONs (2OMePS) and phosphorodia-
midate morpholino oligomers (PMO). Both AONs induce exon
51 skipping and dystrophin restoration at comparable levels
after intramuscular injections in DMD patients (44%–97%
dystrophin positive fibers, 17%–35% dystrophin levels) (Kinali
et al., 2009; van Deutekom et al., 2007). As systemic treatment
is required to target all muscle tissue, the 2OMePS AON was
delivered subcutaneously in phase I/II studies at different doses
by five weekly injections. This treatment resulted in detectable
dystrophin in 10 out of 12 treated patients in 60%–100%of fibersin a dose-dependent manner. Levels up to 15.6% of normal dys-
trophin level were detected in biopsies taken 1 month after the
last treatment, whereas in pretreatment biopsies taken from
three patients, up to 7% of fibers were positive and dystrophin
levels were, at most, 2% of normal. All patients then entered
an open label extension study in which they received weekly
treatment with the highest dose (6 mg/kg). After 12 weeks, a
modest improvement in the 6 min walk test distance was
observed for most patients (Goemans et al., 2011). Lacking
a placebo group and the sample size to assess statistical signif-
icance for the walking test improvement, this finding should be
interpreted with caution. In terms of side effects, injection site
reactions are common for 2OMePS AONs and were indeed
observed in all patients. Several additional trials with this
AON are currently ongoing, including a double-blind placebo-
controlled trial.
For the PMO AON, six different doses (up to 20 mg/kg) were
infused intravenously weekly for 12 weeks. Pretreatment biop-
sies were taken for all patients and increased dystrophin levels
were found in 7 out of 19 patients, including three good
responders who showed up to 55% dystrophin positive fibers
and 11%–22% of normal dystrophin levels. No effect on muscle
function could be detected (Cirak et al., 2011). A significant
decrease in the number of infiltrating T cells was observed in
biopsies from patients in the two highest dose groups, suggest-
ing a reduced inflammatory state of the muscle. Further dose
optimization is currently ongoing in a recently started trial tes-
ting weekly intravenous infusion of higher doses (30 and
50 mg/kg) for 24 weeks (http://www.clinicaltrials.gov/ct2/
results?term=NCT01396239).
The main hurdle for this approach will be its specificity for tar-
geting different mutations, as currently, each AON is considered
a different drug by regulatory authorities and thus has to be
developed separately. In addition, it will not be feasible to
perform large trials for exons affected in small groups of patients.
New clinical trial models to assess safety and efficacy for AONs
must be developed to allow broad clinical applicability.
Restoration of Cryptic Splicing
Mutations can also introduce aberrant splice sites, resulting in
the inclusion or exclusion of an exon or part of an exon.Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1085
Figure 1. Schematic Depictions of Splicing
Modulation of Disease Mutations
Exons are depicted as rectangles or trapezoids
(if causing frame shifts), introns as horizontal lines,
and splicing events as Vs (gray, normal; red,
deleterious; blue, therapeutically induced.
(A) Exon skipping to restore the reading frame.
An out-of-frame deletion of exons 45–50 in
the DMD gene causes a frame shift in the
mRNA, resulting in premature stop codon in
exon 51 (left). Targeting exon 51 with an AON
that hides it from the splicing machinery leads to
exon 51 skipping and partially functional protein
(right).
(B) Restoration of cryptic splicing. A single-
nucleotide mutation within exon 11 of the LMNA
gene introduces a cryptic donor splice site.
Splicing correction can be achieved using AONs
targeting the mutation and the donor splice site
in intron 10.
(C) Restoration of a retrotransposon-induced
cryptic splicing. The SVA retrotransposon
insertion results in a mutant last exon in the
FCMD gene. AONs targeting the acceptor or the
donor or the exonic splicing enhancer within
SVA can block the superfluous splicing event.
(D) Tweaking alternative splicing. The STAT3
a and b isoforms, which are anti- and proapo-
ptotic, respectively, are generated by the use
of a proximal (for a) and a distal (for b) splice
acceptor site in exon 23. An AON targeting the
proximal splice acceptor site can induce a
splicing shift toward the b isoform (left). Alter-
natively, AONs targeting the out-of-frame exon 6
induce skipping and nonsense-mediated decay,
abolishing both STAT3 isoforms (right).
(E) Targeting of extended repeats. A CUG
expansion in the DMPK gene forms hairpins that
sequester MBNL protein. Consequently, alter-
native splicing of genes normally regulated by MBNL1 is deregulated. AONs can bind to the expanded repeats, avoiding hairpin formation and MBNL1
binding and thus normalizing splicing.
(F) Inducing exon inclusion. SMN2 exon 7 is skipped due to a silent mutation. An intronic splicing silencer (ISS) in SMN2 intron 7 can be targeted with an
AON to enhance exon 7 inclusion.Hutchinson-Gilford progeria syndrome is a rare autosomal-
dominant disorder characterized by accelerated aging, growth
impairment, and shortened life span, among other symptoms.
In most patients, the disease is caused by a mutation in exon
11 of the LMNA gene that introduces a cryptic splice site, result-
ing in a shortened protein called progerin. Of note, progerin is
also produced during normal aging, albeit at lower levels and
over a longer time frame. Recently, mice carrying the equivalent
of the humanmutationwere generated that exhibit aspects of the
human disease phenotype (Osorio et al., 2011). PMOs targeting
the donor splice site of exon 10 and/or the mutation in exon 11 of
the Lmna gene (Figure 1B) reduce the production of progerin in
cultured fibroblasts derived from the mouse model in a dose-
dependent manner, with the combination of PMOs targeting
the mutation and the donor splice site outperforming single
PMOs. Human-specific PMOs yielded similar results in patient-
derived fibroblasts. For systemic tests, a combination of vivo-
morpholinos (PMOs covalently linked to an octa-guanidine den-
drimer to facilitate uptake bymost tissues) targeting exon 10 and
exon 11 (6 mg/kg of each AON) were administered intravenously
twice weekly to mice for 12 weeks. This treatment ameliorated
most of the phenotypes and extended survival from 111 to
155 days. These results bode well for the treatment of this1086 Cell 148, March 16, 2012 ª2012 Elsevier Inc.disorder even though the number of patients is low, raising the
same challenges for trials discussed for DMD.
Another example of a syndrome often caused by cryptic
splicing is ataxia-telangiecatasia, an autosomal recessive dis-
ease caused bymutations in theATM gene. This disorder is char-
acterized by progressive neurodegeneration, immunodeficiency,
radiosensitivity, anda high risk for cancer. PMOs linked to an argi-
nine-rich peptide (PPMO, an alternative way to enhance tissue
uptake) targeting twoprototypicATM-splicingmutations restored
normal splicing and ATM protein production and abrogated
radiosensitivity in patient-derived cell lines (Du et al., 2011). As
the most debilitating feature of the disease is the progressive
lossofPurkinje cells in thecerebellum, it is crucial thatAONscross
the blood-brain barrier. Intravenous injections of high doses
(60mg/kg) of a fluorescently labeled PPMOresulted in green fluo-
rescence throughout the brain, with high expression in the Pur-
kinje cell layer, suggesting that these PPMOs can target the
central nervous system, at least in mice (Du et al., 2011). Follow-
up studies with ATM-targeting PPMOs will be needed to learn
their efficacy in terms of functional targeting and dose toleration.
The autosomal recessive Fukuyama congenital muscular dys-
trophy (FCMD) results from insertion of a SVA (SINE-VNTR-Alu)
retrotransposon into the FCMD gene. It was recently shown
that this insertion causes aberrant activation of a cryptic donor
splice site in the last exon of this gene and an acceptor splice
site in the retrotransposon, leading to loss of the distal part of
the last exonand inclusionof a retrotransposon-derivedexon (Ta-
niguchi-Ikeda et al., 2011) (Figure 1C). Consequently, the fukutin
protein lacks its C-terminal 38 amino acids and instead contains
129aminoacidsderived from theSVAsequence, causingmisloc-
alization of fukutin to the endoplasmic reticulum instead of the
Golgi apparatus. It cannot therefore properly glycosylate a-dys-
troglycan, leading to disrupted interactions with extracellular
matrix proteins like laminin. A knockin mouse model containing
human exon 10 and the SVA retrotransposon showed the same
splicing abnormality and recapitulated the hypoglycosylation of
a-dystroglycan. 2OMePS AONs targeting the acceptor or donor
splice site or the exonic splicing enhancer of the SVA exon
restored normal splicing in cultured cells to some extent, and
a cocktail containing AONs targeting each of these sites worked
efficiently (Taniguchi-Ikeda et al., 2011) (Figure 1C). Local intra-
muscular and systemic injections of vivo-morpholino counter-
parts restored splicing and rescued levels of functional fukutin
protein. Retrotransposon-induced aberrant splicing has been
confirmed for at least two other genetic diseases (autosomal
recessive hypercholesterolemia and lipid storage disease with
subclinical myopathy) (Taniguchi-Ikeda et al., 2011), and splicing
abnormalities have not yet been investigated for other diseases
with retrotransposon insertions. It may be that incorporation of
retrotransposon sequences into exons is a common disease
mechanism for which antisense-mediated exon skipping would
provide a potential therapeutic tool.
Tweaking Alternative Splicing
In most cancers, alternative splicing of many genes is disrupted.
Some genes can produce both oncogenic and tumor suppressor
proteins based on the inclusion or exclusion of specific exons.
STAT3, a transcription factor implicated in cytokine and growth
factor signaling, is activated via transient phosphorylation of
monomers, which then dimerize and translocate to the nucleus.
Persistent phosphorylation of STAT3 is observed in the majority
of human cancers. There are two main STAT3 isoforms: the
full-length STAT3a and STAT3b that lacks part of exon 23 due
to an alternative splicing event recognizing an acceptor splice
site within exon 23. STAT3b lacks the transactivation domain
but can still dimerize with STAT3a and bind to DNA without
inducing transcriptional activity. It thus may act in a dominant-
negative manner to induce apoptosis and inhibit tumor growth
but has recently been shown to also downregulate expression
of additional genes involved in proliferation and cancer (Zam-
marchi et al., 2011). A PMO targeting the acceptor splice site
of STAT3a exon 23 was able to induce a switch from STAT3a
to STAT3b (Figure 1D) in cultured tumor cell lines, leading to
increased cell death for two out of three tested tumor cell lines.
In vivo, injections of the vivo-morpholino counterparts of this
PMO into implanted tumors were able to bring about a similar
switch in STAT3 isoform expression, which resulted in tumor
regression, a lower mitotic index, and improved morphology.
Knockdown of both isoforms through vivo-morpholino-induced
skipping of the out-of-frame exon 6 (Figure 1D) did not have
any notable effects on tumor growth morphology, apoptosis,and mitosis, in line with the additional functions ascribed to
STAT3b (Zammarchi et al., 2011). This example illustrates how
AON-mediated exon skipping can serve both as a tool to eluci-
date functions of different isoforms and as a therapeutic
approach. The biggest hurdle to developing AON-mediated
exon skipping as a cancer therapy will be tumor delivery. Intratu-
mor delivery may be the preferred route, as delivery to tumors
through systemic administration is difficult. However, unlike the
case for many genetic diseases in which a minor increase in
protein level is anticipated to be therapeutically beneficial, for
cancer, it is crucial that no tumor cells escape treatment. Intratu-
mor delivery will miss cells that have metastasized.
Another disease caused by disrupted alternative splicing is
myotonic dystrophy. In myotonic dystrophy type 1, expression
of an expanded repeat in transcripts of the DMPK gene leads
to aggregates of mRNA that sequester the splicing factor
muscleblind-like 1 (MBNL1), resulting in a switch from an adult
to a fetal splicing pattern for multiple genes. Rather than using
AONs to revert splicing of each and every misspliced transcript,
it has been feasible to use PMO and 2OMePS AONs that target
repeats to correct the defects. This targeting disrupts the aggre-
gated DMPK transcripts in patient-derived cells and a mouse
model containing CUG repeats inserted in the 30UTR of the
human actin gene, which leads to similar splicing abnormalities
as observed in myotonic dystrophy patients (Mulders et al.,
2009; Wheeler et al., 2009) (Figure 1E). Treatment with these
AONs normalized splicing in cultured cells and the mouse
model after intramuscular injection (Wheeler et al., 2009). It
was recently shown that splicing abnormalities may also occur
in polyglutamine diseases such as spinal cerebellar ataxia 3
and Huntington’s disease that are caused by shorter CAG
repeats (Mykowska et al., 2011), and that ALS is frequently
caused by expanded hexanucleotide repeats (DeJesus-Hernan-
dez et al., 2011). Thus, repeat targeting AONs may be more
widely applicable than just for myotonic dystrophy.
Inducing Exon Inclusion
Spinal muscular atrophy is an autosomal recessive disease
caused by mutations affecting the SMN1 gene. The homologous
SMN2 gene cannot functionally compensate for SMN1 muta-
tions because exon 7 is skipped in the majority of SMN2 tran-
scripts, resulting in an unstable protein. In the absence of
SMN1, functional SMN protein is produced only from the 10%
of SMN2 transcripts in which exon 7 is included. As the severity
of the disease inversely correlates with the number of SMN2
gene copies present, and with the amount of SMN protein
produced, increasing the inclusion of exon 7 is expected
to ameliorate disease symptoms. 20-O-methoxyethyl phos-
phorothioate (2OMoePS) AONs targeting splicing silencers
(sequences bound by splicing factors that induce exon exclu-
sion) have been identified that can improve exon 7 inclusion
(Hua et al., 2008) (Figure 1F). As spinal muscular atrophy is
primarily caused by loss of motor neurons and typical AONs
do not cross the blood-brain barrier, delivery into the central
nervous system was thought to be required. Postnatal intraven-
tricular AON injections indeed improved survival from 10 to
16 days in a severe mouse model (Hua et al., 2011). However,
when these mice were injected subcutaneously with high dosesCell 148, March 16, 2012 ª2012 Elsevier Inc. 1087
of AON, a median survival of 108 days could be achieved,
whereas combined subcutaneous and intraventricular treatment
improved this to 173 days. This implies that, at least in mice,
restoration of SMN, which is involved in small nuclear ribonu-
cleoprotein particle biogenesis, in other tissues is crucial for
improving survival. Exon 7 inclusion and expression of SMN
protein was increased in the spinal cord, brain, liver, heart,
kidneys, and skeletal muscles. Treated animals were generally
smaller, weighed less, and had shorter tails than heterozygous
littermates, but most could climb and run and exhibited
improved strength and normal neuromuscular junctions.
Bifunctional AONs have also been tested as a way to improve
SMN2 exon 7 inclusion (Osman et al., 2011). A 2OMePSAON tar-
geting an intronic splicing silencer in intron 7 canbemodifiedwith
an oligonucleotide tail that recruits exon inclusion factors, further
enabling exon 7 recognition and inclusion into SMN2 transcripts.
Tailed AONs induced more exon 7 inclusion and higher SMN
protein levels in patient-derived cells and a mouse model than
did regular AONs. Intraventricular treatment with both the non-
tailed and tailed AONs modestly increased survival, with the
tailed AONs again outperforming the regular AONs. A putative
disadvantage of this approach is that tailed AONs are relatively
long, whichmay hamper tissue uptake upon systemic treatment.
Familial dysautonomia is an autosomal recessive, congenital
sensory neuropathy caused by aberrant splicing of the IKBKAP
gene, leading to reduced levels of the ikappaB kinase complex
associated protein (IKAP) that potentially causes IKAP protein
levels to dropbelow the amount required for normal development
and differentiation. Nearly all patients are homozygous for
a mutation in intron 20 leading to the frequent skipping of exon
20 in the IKAP transcript. IKAP has many functions, including
transcriptional elongation of genes involved in cell migration
and adhesion, and complete lack of IKAP is embryonic lethal.
Interestingly, exon 20 inclusion could be improved in a mouse
model containing a BAC with the mutated human IKBKAP gene
using kinetin, a plant cytokine, via an as yet unidentified mecha-
nism (Shetty et al., 2011). Daily oral treatment (either by gavage or
in food) was tolerated well by the mice, and pharmacokinetic
studies confirmed that kinetin was able to pass the blood-brain
barrier. Exon 20 inclusion and IKAP protein levels were increased
in all tissues analyzed, and kinetin treatment in primary neuronal
cells derived from this mouse model showed a dose-dependent
increase of exon 20 inclusion and protein levels. The fact that
kinetin can be delivered orally facilitates its clinical development,
although it is not yet knownwhether increasing levels of IKAPwill
be therapeutic in patients, as part of the neurodegeneration is
already present at birth andmay therefore be irreversible. Never-
theless, such treatmentmay still halt or slow further neurodegen-
eration. Kinetin has also been shown to improve exon inclusion in
mutated neurofibromin 1 transcripts and may therefore be more
widely applicable (Pros et al., 2010). It has not yet been investi-
gated whether kinetin treatment also influences splicing of other
genes in a detrimental manner; so far, the treatment appears to
be well tolerated by mice.
Perspective
Taken together, these recent results underscore that therapeutic
splicing modulation with chemical compounds or AONs has1088 Cell 148, March 16, 2012 ª2012 Elsevier Inc.great potential for treating many diseases. It has reached phase
3 clinical trial for DMD andmight become clinically applicable for
this disease in the near future. Certainly, there are hurdles that
still must be overcome such as improved delivery and specificity;
nevertheless, splicing modulation offers hope for combating
many genetic diseases that are currently untreatable.
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